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Induction of anesthesiaAbstract Introduction: Fentanyl induced cough (FIC) often follows bolus fentanyl administration
in 18% up to 65% of cases. Several researches have been done to reduce such side effect. Our
hypothesis is that pretreatment with intravenous dexmedetomidine–magnesium sulfate could effec-
tively suppress fentanyl induced cough.
Patients and methods: 200 patients of (ASA) I and I aged 18–60 years, weighting from 40 to 90 kg,
undergoing elective surgeries, were randomized into four groups using sealed envelope system.
Patients belong to (D) group received DEX 0.5 lg/kg. Patients belong to group (M) received mag-
nesium sulfate 20 mg/kg, and those of group (D +M) received DEX 0.5 lg/kg + magnesium sul-
fate 20 mg/kg. The above preparations were reconstructed by saline to reach a volume of 20 ml.
Patients belong to group (S) received 20 ml normal saline. Patients of each group received their
cross bonding drug one minute before fentanyl bolus injection (2 lg/kg within 5 s). The primary
end points were the onset time, frequency and severity of cough from time of fentanyl injection till
1 min. According to four point scale, severity of cough was graded as follows: grade 0 = no cough;
grade 1 = single cough; grade 2 = more than one attack of non- sustained cough; grade
3 = repeated and sustained cough with head lift.
Results: Nineteen (38%) cases had cough in group (S), 8(16%) in group (D) and 14(28%) cases in
group (M). No patients in group (D +M) experienced any cough. Patients of groups (D) and
(D +M) showed a significantly lower incidence of cough compared with group (S) (P< 0.05). There
was no significant difference regarding the onset time or severity of cough between groups.
Conclusion: Pretreatment with dexmedetomidine–magnesium sulfate could effectively suppress
fentanyl induced cough following injection of 2 lg/kg fentanyl injected within 5 s.
 2016 Publishing services by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
334 E.A. El Motlb1. Introduction
Due to some sympathetic and psychological side effects that
may occur during induction of general anesthesia, opioids
and particularly fentanyl are used for analgesia and to relieve
anxiety [1,2]. Fentanyl is characterized by the rapid onset,
short duration, effective analgesia, less histamine release, no
negative inotropic action plus it can be titrated easily [3]. How-
ever, fentanyl induced cough (FIC) often follows bolus fen-
tanyl administration in 18% up to 65% of cases [4]. Several
researches have been done to reduce such side effect which is
a critical issue in those suffering from intracranial hyperten-
sion, cerebral or aortic aneurysm, increased intra-abdominal
or intraocular pressure, pneumothorax or hyperactive air
way diseases [5,6]. FIC may be simple or may be severe enough
to cause upper air way obstruction that necessitates immediate
intervention [6]. Bronchoconstriction was expected to be the
engine of this cough reflex, so bronchodilators (selective b2
agonist) inhalation was used. Others such as lidocaine, N-
methyl-D-aspartate (NMDA) receptor antagonists, atropine,
propofol, midazolam and slow administration of fentanyl were
tried [7,8]. Dexmedetomidine (DEX) is a specific a2-receptor
agonist, used to reduce anxiety and tension and to promote
relaxation and sedation with hemodynamic stability [9]. Mag-
nesium (Mg) is a major cation in the human body that antag-
onizes calcium influx into the cell through a noncompetitive
mechanism at N-methyl-D-aspartate (NMDA) receptor [10]
and helps to increase flaccidity [11], as well; it inhibits contrac-
tion of smooth muscle and may be helpful in treatment of
asthma [12]. This study aims to investigate the efficacy of
DEX–Mg SO4 to prevent or suppress FIC. The hypothesis
of this study is that DEX–Mg SO4 complex is a powerful
and effective regimen for suppression of FIC.2. Patients and methods
This prospective, randomized, double blind, controlled study
took approval of Mansoura Medical Research Ethics Commit-
tee. The study was conducted in Mansoura University Hospi-
tal (Oncology center) and after obtaining written informed
consent. 200 American Society of Anesthesiologists (ASA)
physical status I and I patients with age range from 18 to
60 years and body weight from 40 to 90 kg who were undergo-
ing general anesthesia for different elective surgeries were
included in our study. Patients suffering from hyperactive air-
way, upper respiratory tract infection, expected difficult air-
way, hepatic or renal impairment, uncontrolled hypertension,
coronary artery disease, and diabetes and those receiving anes-
thetic premedication were excluded from the study. Patients
were randomly assigned to one of the four following groupsTable 1 Demographic data in four groups. Values are in means ±
Demographics Group S (n= 50) Group D (n= 50)
Age (years) 40.3 ± 11.1 39.8 ± 12.3
Gender male/female 27/23 26/24
Weight (kg) 80.9 ± 8.4 78.5 ± 5.3
Height (cm) 161.8 ± 7.2 165.6 ± 5.5
ASA class I/II 46/4 43/7
No significant difference was detected in this table.using sealed envelope system: Group S (control group), Group
D (DEX group), Group M (magnesium sulfate group) and
Group D-M (DEX–magnesium sulfate group). I used sealed
envelope system through prepared randomly generated treat-
ment allocations within sealed envelopes. Once a patient has
consented to enter the trial an envelope is opened and the
patient is offered the allocated treatment regimen. The anes-
thetics were prepared by an anesthesiologist, who was no fur-
ther involved in data collection. Patients included in this study
didn’t receive any premedication before surgery. On arrival to
the operating room, pressure cuff, pulse oximetry probe and
ECG electrodes were connected to the patient. An intravenous
access (20 G cannula) was inserted. Patients belong to (D)
group received DEX 0.5 lg/kg+ normal saline to reach a vol-
ume of 20 ml. Patients belong to group (M) received magne-
sium sulfate 20 mg/kg+ normal saline to reach a volume of
20 ml, and those of group (S) received normal saline of 20 ml
volume. Patients belong to group (D-M) received DEX
0.5 lg/kg + magnesium sulfate 20 mg/kg+ normal saline to
reach a volume of 20 ml. Patients of each group received their
cross bonding drug by steady rate over 10 min-one minute
before fentanyl bolus injection (2 lg/kg within 5 s).
The primary end points were the onset time (time from end
of bolus injection of fentanyl till beginning of cough), fre-
quency and severity of cough. These parameters were recorded
by an anesthesiologist blind to group assignment, from time of
fentanyl injection till 1 min. According to four point scale,
severity of cough was graded as follows: grade 0 = no cough;
grade 1 = single cough; grade 2 = more than one attack of
non-sustained cough; grade 3 = repeated and sustained cough
with head lift. Later, by 1–2 mg propofol, anesthesia was
induced and maintained with inhalational agent and/or propo-
fol infusion plus air/oxygen mixtures.Statistical analysis
Data were analyzed using SPSS (Statistical Package for Social
Sciences) version 22.0. Qualitative data were presented as num-
ber, proportion or percentage. Comparison between groups
was done by Chi-square test or Fisher’s exact test with Bonfer-
roni correction. Quantitative data were tested for normality by
Kolmogrov–Smirnov test. Normally distributed data were pre-
sented as mean ± SD. F test (ANOVA) was used to compare
between groups. P 6 0.05 was considered to be statistically
significant.
Post hoc power analysis was done using G power program
(version 3.0.10) to calculate the power of this study. Chi-
square (v2) test (contagency tables) was used with effect
size = 0.3 (medium), a error = 0.05, total sample size = 200
and degree of freedom = 3. Calculated power was 0.95.SD.
Group M (n= 50) Group D+M (n= 50) P
40.9 ± 10.9 38.6 ± 14.1 0.63
22/28 24/26 0.75
79.3 ± 1.2 80.6 ± 4.3 0.76
162.4 ± 8.1 164.3 ± 4.6 0.81
42/8 47/3 0.32
Suppression of fentanyl-induced cough 3353. Results
No significant differences were recorded regarding the demo-
graphic data in the four groups (Table 1). Nineteen (38%)
cases had cough in group (S), 8(16%) in group (D) and 14
(28%) cases in group (M). No patients in group (D +M)
experienced any cough. Patients of groups (D) and (D +M)
showed a significantly lower incidence of cough compared with
group (S). There was no significant difference regarding the
onset time or severity of cough between groups (see Chart 1
and Table 2).Assessed for
eligibility (n=20
R  
Randomiza
(n=200)
Allocated to receive 
drug (S) (n=50)
Received allocated 
drug (n=50)
Didn't receive 
allocated drug (n=0) 
Allocated to receive drug 
(D) (n=50)
Received allocated drug 
(n=50)
Didn't receive allocated 
drug (n=0)
Lost to follow up ll 
inducon of 
anesthesia (n= zero)
Lost to follow up ll 
inducon of 
anesthesia (n= zero)
Analyzed 
(n=50)
Analyzed 
(n=50)
Analysi
Follow u
Allocaon
Enrollment
Chart 1 Flowchart of participants’ pro4. Discussion
Multiple mechanisms are thought to be involved in occurrence of
FIC during induction of anesthesia. Fentanyl could inhibit cen-
tral sympathetic outflow leading to vagal predominance, causing
cough and reflex bronchoconstriction [13,14]. Another possible
explanation is pulmonary chemo reflex as fentanyl-induced tra-
cheal smooth muscle constriction leads to stimulation of irritant
receptors in the upper pulmonary mucosa or vagal C-fiber
receptors located proximal to pulmonary blood vessels [15].
Also, it’s suspected that intravenous fentanyl through its action 
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Table 2 Incidence, the onset time and severity of cough after intravenous fentanyl administration. Values are in mean ± SD or
number (%).
Group Incidence of cough (%) Onset(s) Severity of cough (%)
Mild Moderate Sever
Group S 19(38%) 18.6 ± 2.9 8(42.1%) 5(26.3%) 6(31.6%)
Group D 8(16%)* [p= 0.02] 19.8 ± 3.4 3(37.5%) 3(37.5%) 2(25%)
Group M 14(28%) [p = 0.32] 19.0 ± 1.8 6(42.9%) 4(28.6%) 4(28.6%)
Group D±M 0(0%)* [p< 0.001] – – – –
* P is significant if 6 0.05 at confidence interval 95% (in comparison with group S).
336 E.A. El Motlbon prejunctional l-opioid receptors leads to release of histamine
and neuropeptides that contribute to coughing [16].
Various studies have shed light on the potential harmful
effects of FIC [5,17–19,20]. Therefore, many agents such as
intra-venous ephedrine, lidocaine, dexamethasone or inhala-
tion of sodium chromoglycate, salbutamol or beclomethasone
have been tried and were documented as successful agents in
suppressing FIC [21].
In this study, a dose of 2 lg/kg fentanyl fits the usual daily
administration in our theaters. Interestingly, this study demon-
strated that a priming dose of DEX–magnesium sulfate could
suppress FIC completely in comparison with 38%, 16% and
28% in placebo, DEX and magnesium sulfate groups,
respectively.
None of patients in this study received premedications, and
this could explain higher incidence of cough in control group
(38%) compared to 16%, 28%, 0% in DEX, magnesium sul-
fate and DEX–magnesium sulfate groups, respectively. But
the incidence of cough in our control group was lower than
that was documented by Yu et al. [22]. This can be attributed
to a lower dose of fentanyl used in current study (2 lg/kg)
compared to 3 lg/kg in the study of Yu, in addition to a slower
injection of fentanyl over a duration of 5 s in this study com-
pared to a duration of less than 2 s in the study of Yu. So, it
seems wise not to inject fentanyl over duration less than 5 s.
Regarding the onset time of cough, the control group
showed a shorter onset time than recorded for groups D and
M but without significant difference between groups. Similarly
the severity of cough didn’t carry any significant difference
between these groups.
DEX is a specific a2-receptor agonist, used to reduce anxi-
ety and tension, and to promote relaxation and sedation with
hemodynamic stability [9]. In the current study, DEX was used
successfully in a dose of 0.5 lg/kg to suppress FIC with a sig-
nificant lower incidence of cough (16%) compared to (38%) in
control group.
The effectiveness of DEX in suppressing FIC was reported
by He et al. using two doses (0.5 lg/kg and 1 lg/kg) [23]. DEX
was used successfully in combination with other agents such as
midazolam and ketamine to suppress FIC [4,22].
Cough induced by opioid mostly is self-limited as reported
by Baily [2]. But Yu et al., in their pilot study reported that
some patients had to restrain themselves from cough after
receiving fentanyl intravenously [22]. The sedative effect of
DEX resembles that happen in normal sleep through inhibi-
tion of norepinephrine release from locus ceruleus that leads
to stimulation of the release of GABA and galanin by ventro-
lateral preoptic nucleus (VLPO). These neurotransmitterscause further suppression of norepinephrine release from locus
ceruleus and inhibit histamine release by tuberomamillary
nucleus (TMN) leading to hypnotic state [23,24]. So, sedative
effect of DEX not alters self-control ability of FIC. And this
is an advantage for DEX if we know that midazolam in a dose
of 0.06 mg/kg altered the self-control ability and can’t suppress
FIC as reported by Yu et al. [22].
Another explanation, in a study conducted in dogs by Groe-
ben et al., they reported the ability of intravenous DEX to
block histamine induced bronchoconstriction completely [25].
On the other hand, magnesium sulfate can increase depth of
anesthesia through suppression of central nervous system and
can increase flaccidity by its calcium antagonist properties [11].
Beside this, asthmatic patients can get benefit from magnesium
sulfate through its inhibitory effect on smooth muscle contrac-
tion [12].
Shideh et al. reported that magnesium sulfate in a dose of
15 mg/kg induced non-significant reduction in incidence of
cough and laryngospasm in those undergoing tonsillectomy
after tube removal. However incidence of cough and laryn-
gospasm was lower than control group [26].
A dose of 40 mg /kg magnesium sulfate was reported by
Fuch-Buder et al. to be safe for clinical use. Either by clinical
examination or by electromyography, it didn’t cause marked
neuromuscular block or symptoms of muscle weakness [27].
In the current study, a dose of 20 mg/kg was selected but it
failed to achieve significant decrease in incidence of cough
compared with control group. However, the combination of
magnesium sulfate and dexmedetomidine can suppress FIC
completely that can be attributed to the combined effects of
both drugs as explained before.
One limitation in this study is that we select a dose of
20 mg/kg of magnesium sulfate which reduced the incidence
and severity of cough compared to control group but failed
to register a significant difference. So, I recommend trying
higher doses of magnesium sulfate that may be more effective
in controlling cough.
In conclusion, this study shows that pretreatment with
dexmedetomidine–magnesium sulfate could effectively sup-
press fentanyl induced cough following injection of 2 lg/kg
fentanyl within 5 s during induction of general anesthesia.
So, this technique could be an effective alternative for attenu-
ating FIC.Conflict of interest
We have no conflict of interest to declare.
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